madam professor
madam professor Post-Buyout, Genentech’s DNA Is Dominant By Dermot Doherty and Rob Waters July 01, 2010 When Roche Holding executives held an investor-day briefing in New York in March, Morgan Stanley analyst Andrew Baum had a question that had nothing to do with new drugs, licensing deals, or health-care legislation. Did the Genentech team hide […]